leisure time -WSS

leisure time

author：knowledge 2025-09-06 03:54:56 - browse：126

3D DNA on a sheet of paper listing nucleic acid sequences — coverage from STAT — Adobe

Ultima Genomics, an upstart some observers have called a “dark horse” in the world of DNA sequencing, will soon launch a line of high-power instruments that can read a human genome for as little as $100, the company’s leadership told STAT.

The sequencer, dubbed the UG 100, is a $1.5 million machine that can read up to 20,000 human genomes a year. The reagents required to operate the instrument cost as little as $1 per billion sequenced DNA bases; that translates to $100 per genome assuming each base in the 3-gigabase human genome is read 33 times, a common industry standard. The company plans to officially launch the product at this year’s Advances in Genome Biology and Technology meeting, which kicks off in Orlando, Fla., on Feb. 5.

The product’s cost and maximum output put it roughly in the same range as a line of high-throughput instruments launched in September 2022 by Illumina, which controls an estimated 80% of the sequencing market. But Ultima is hoping it can chip into the sequencing giant’s market share among genome centers, large clinical labs, and others with an appetite for reams of genetic data by offering lower operating costs and greater flexibility.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Generate Biomedicines machine learning biotech raises $273M

leisure time

WSS

Congress must protect the remaining independent doctors

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Private equity could exacerbate cardiology's overuse problem, experts fear

How medical schools plan to diversify without affirmative action

Juul documents reveal insider tactics on political lobbying

How to make the FDA’s new prescription one

explore

leisure time

entertainment

Dobbs anniversary: the lost opportunity of abortion as health care

FDA panel endorses Alnylam’s heart drug — after picking it apart

Drug repurposing or repositioning? The language matters

White House touts steps to stem shortages of cancer treatments

Hepatitis C has a cure — but many Americans still lack access to it

ACIP vaccine advisory panel sees its vacancies filled

Hepatitis C has a cure — but many Americans still lack access to it

Here’s what’s in the FDA plan to include pregnant women in clinical trials

United colonoscopy coverage change 'may cost lives,' doctors say

Bernie Sanders gets little from pharma CEOs on drug prices

leisure time

Bernie Sanders gets little from pharma CEOs on drug prices

PEPFAR is under serious threat — and so is global health

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Will the IRA bring competition to the biologics market?

White House touts steps to stem shortages of cancer treatments

FDA proposes changes to key medical devices approval pathway

leisure time

entertainment

knowledge

knowledge